Methods of using transporter-like molecules to treat pain and pain-related disorders
AssigneeMillennium Pharmaceuticals, Inc.
InventorsAndrew D. J. Goodearl, Inmaculada Silos-Santiago
Life of this patent
Estimating the term…
Abstract
The invention relates to OCT-3 polypeptides, nucleic acid molecules encoding OCT-3, and uses thereof. OCT-3 is a protein that is expressed in the plasma membrane of biological cells, across which it regulates the transport of organic molecules.
Claims17
A method for identifying a compound capable of treating a pain disorder comprising assaying the ability of the compound to modulate the expression of an organic cation transporter 3 (OCT-3) nucleic acid, thereby identifying a compound capable of treating a pain disorder.
A method for identifying a compound capable of treating a pain disorder comprising assaying the ability of the compound to modulate the activity of an organic cation transporter 3 (OCT-3) polypeptide, thereby identifying a compound capable of treating a pain disorder.
A method for identifying a compound capable of modulating an organic cation transporter 3 (OCT-3) activity, comprising:
- (a) contacting a cell which expresses OCT-3 with a test compound;
- and
- (b) assaying the ability of the test compound to modulate the expression of an OCT-3 nucleic acid or the activity of an OCT-3 polypeptide, thereby identifying a compound capable of modulating an OCT-3 activity.
A method for identifying a compound capable of modulating an organic cation transporter 3 (OCT-3) activity, comprising:
- (a) contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 4, or 6 with a test compound;
- and
- (b) assaying the ability of the test compound to modulate an activity of the polypeptide, thereby identifying a compound capable of modulating an OCT-3 activity.
A method for modulating an OCT-3 activity comprising contacting an OCT-3 polypeptide or a cell expressing an OCT-3 polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the OCT-3 activity.
A method for treating a subject having a pain disorder characterized by aberrant OCT-3 polypeptide activity or aberrant OCT-3 nucleic acid expression, comprising administering to the subject an OCT-3 modulator, thereby treating the subject having a pain disorder.
A pharmaceutical formulation for the treatment of a pain disorder, comprising a compound that activates an organic cation transporter 3 (OCT-3) polypeptide activity or an OCT-3 nucleic acid expression, mixed with a pharmaceutically acceptable carrier.
A genetically engineered nonhuman mammal in which the expression of an oct-3 gene has been inactivated.
A transgenic animal which expresses a human oct-3 gene.
Dependencies are inferred from the claim text.